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Purpose: To evaluate the safety and efficacy of DisCoVisc ophthalmic viscosurgical device 
(OVD, Alcon Laboratories, Inc) with respect to a comparator, Healon OVD (Advanced Medi-
cal Optics, Inc).
Patients and methods: In this prospective study, patients with cataracts were randomized to 
an OVD, and then received phacoemulsification and injection of an intraocular lens. After each 
surgery, unmasked investigators completed subjective questionnaires about OVD characteristics 
during each stage of the procedure. Masked technicians evaluated objective safety parameters 
of intraocular pressure (IOP) and endothelial cell density, with 90 days of follow-up.
Results: The DisCoVisc OVD group (128 eyes) and the Healon OVD group (121 eyes) had 
statistically similar outcomes for IOP and for endothelial cell loss. Subjectively assessed vis-
cosity was statistically different (P , 0.0001), with Healon OVD most often rated “cohesive” 
and DisCoVisc OVD most often rated “both dispersive and cohesive”. Workspace maintenance 
differed between groups (P , 0.0001), with workspace most frequently rated “full chamber 
maintained” when using DisCoVisc OVD and most frequently rated “workspace maintained” 
when using Healon OVD. “Flat” or “shallow” workspace ratings occurred only in the Healon 
OVD group.
Conclusion: DisCoVisc OVD had both cohesive and dispersive properties, and was safe and 
effective for every stage of cataract surgery.
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Introduction
Viscoelastics, or ophthalmic viscosurgical devices (OVDs), facilitate cataract surgery 
by maintaining the depth and shape of the anterior chamber. This provides a workspace 
for the surgeon and provides a viscous barrier that protects the delicate corneal endothe-
lium from surgical instruments, from cataractous lens debris, and from the intraocular 
lens during insertion.1 Early OVDs were classified as either cohesive or dispersive, on 
the basis of objective rheological properties.2 Cohesive OVDs are useful in creating 
and maintaining space in the anterior chamber.1 Because cohesive OVDs tend to hold 
together as a mass, they are relatively easy to remove as a bolus at the end of surgery.1 
In contrast to cohesive OVDs, dispersive OVDs spread out when injected into the eye, 
making these substances less effective for maintaining space but more effective for 
coating and protecting intraocular tissues.3 Irrigation/aspiration tends to pull away bits 
and fragments of dispersive OVDs, making these materials more difficult to remove at 
the end of surgery.1,3 The different properties of cohesive and dispersive viscoelastics 
broaden the opportunities for a surgeon’s selection of an OVD for cataract surgery.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The two OVD types – cohesive and dispersive – can be 
used for different stages of the surgery or for different types 
of eyes. For example, a cohesive OVD could be selected to 
expand a small pupil, but a dispersive OVD could be used 
to protect an eye with a compromised corneal endothelium.1 
Some surgical strategies, such as the soft-shell technique, use 
two OVD types together in layers or serially.4 For convenience 
to the surgeon, manufacturers may package two OVD types 
together, as with the DuoVisc viscoelastic system (Alcon 
Laboratories, Inc, Fort Worth, TX).
The endothelium-protecting efficacy of an OVD can be 
evaluated in terms of postoperative measurements of endothe-
lial cell density. Endothelial cell loss occurs during surgery 
and during the postoperative phase, and the loss can continue 
at a faster-than-normal rate for at least 10 years thereafter.5 If 
the normal endothelial cell density of ∼2400 cells/mm2 falls 
below 300–500 cells/mm2, corneal edema can develop, and 
can be followed by decompensation into bullous keratopathy.6 
Rheological properties indicate that a dispersive OVD, with 
its propensity to coat and protect intraocular tissues, might 
be better than a cohesive OVD for endothelial protection.
While an ideal OVD would completely coat and protect 
intraocular tissues during surgery, an ideal OVD also would 
be able to be completely removed from intraocular tissues at 
the conclusion of surgery. Residual OVD left in the eye can 
clog the trabecular meshwork, leading to a transient elevation 
in postoperative intraocular pressure (IOP).7–9 This ocular 
hypertension is sometimes treated with IOP reducing medica-
tion, either prophylactically or in response to postoperative 
observations of IOP spikes to $30 mmHg10 or $35 mmHg.11 
Alternatively or in addition to IOP treatment, a surgeon can 
attempt to avoid IOP spikes by selecting an OVD that is con-
ducive to complete removal at the end of surgery. Rheological 
properties indicate that a cohesive OVD, with its propensity 
to be removed as a bolus, might be better than a dispersive 
OVD for avoiding IOP spikes.
Facilitation of surgical techniques, ability to protect 
endothelium, and avoidance of IOP spikes are all factors that 
need to be considered in selecting an OVD, but these consid-
erations sometimes work at cross purposes; no single OVD is 
a clear choice. In an attempt to provide surgeons with a single 
OVD that was suitable for all phases of surgery, one manufac-
turer (Alcon) developed DisCoVisc OVD. This OVD exhibited 
both dispersive and cohesive properties in bench testing, and 
thus was given the new classification “viscous dispersive”.2 The 
duality was intended to preclude the need for multiple OVDs 
during cataract surgery, while providing good endothelial 
protection and avoiding postoperative IOP spikes.
This manuscript presents the clinical data that were pro-
vided to the US Food and Drug Administration to support the 
approval of DisCoVisc OVD for ophthalmic use. A cohesive 
OVD, Healon (1% hyaluronic acid, Advanced Medical 
Optics, Inc, Santa Ana, CA), was used as a comparator. 
Surgeons assessed the surgical characteristics of the OVDs 
at the conclusion of each surgery, and patients were evalu-
ated for postoperative intraocular pressure and endothelial 
cell density. Overall, the study was designed to investigate 
whether DisCoVisc OVD was safe and effective for every 
stage of the phacoemulsification surgical procedure.
Material and methods
Patient enrollment and baseline
Each of the nine investigators, at nine clinical sites in the 
US, prospectively enrolled 20 to 44 patients. Each patient 
had only one eye enrolled in the study. At least 125 eyes per 
treatment group (250 in total) were targeted for enrollment, 
because calculations had indicated that 113 eyes per group 
would be required to yield a minimally detectable difference 
of 13% (noninferiority margin between groups) in eyes with 
IOP $ 30 mmHg. Guidance from the relevant protocol from 
the International Organization for Standardization12 was used 
to generate these target enrollment numbers and to set the IOP 
safety limit. Calculations included the assumption that 30% 
of patients in each group would have IOP $ 30 mmHg.
Eligible patients were 18 years or older and were 
scheduled for removal of a cataract by phacoemulsification 
  followed by implantation of a posterior chamber intraocu-
lar lens. Each patient’s nonsurgical eye was required to 
be functional, as assessed by the investigator. Exclusion 
criteria related to endothelial cell density of the operative 
eye were a baseline endothelial cell density of less than 
1500 cells/mm2 or a poor quality photograph of preopera-
tive endothelial cells. Exclusion criteria related to IOP in 
the operative eye were as follows: any abnormality that pre-
vented reliable Goldmann applanation tonometry, glaucoma 
or other causes of compromised aqueous humor outflow, 
ocular   hypertension .21 mmHg, or lens pseudoexfoliation 
  syndrome. Operative eyes could not have iris atrophy, a 
history of chronic or recurrent inflammatory eye disease, 
proliferative diabetic retinopathy, previous ocular trauma 
or surgery, or a congenital ocular anomaly. All patients 
signed consent forms in accordance with the Declaration of 
Helsinki. Each investigator received ethical approval from 
an Institutional Review Board.
Central corneal endothelial cell densities were measured 
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Medical, Inc, Irvine, CA), such as a Noncon Robo SP-8000 
with KSS software. Each study site obtained two images of 
the central cornea of each operative eye. Individuals were 
excluded from the study if their baseline endothelial cell 
images were of poor quality (having cell borders that were 
not easily distinguishable). Images were sent to a central 
treatment-masked reading center (Alcon Research, Ltd) that 
measured corneal endothelial cell densities. For each eye, 
the masked reading center selected the photo that showed 
better-quality cell borders and attempted to mark at least 
100 contiguous cells on each image, in order to obtain an 
analysis of at least 50 cells. If the reading center was unable 
to obtain accurate measurements from the first selected photo, 
the second photo was used for the calculation.
Treatment-masked observers at each site assessed IOP 
via Goldmann applanation tonometry. In order to provide 
an accurate representation of the effect of the OVDs on 
the IOP, prophylactic IOP-reducing medications were not 
permitted before, during, or immediately after surgery. 
For patient safety, IOP-reducing therapies were allowed at 
6 hours postoperative and/or at 24 hours postoperative, if 
IOP reached $30 mmHg. This design ensured that the 6-hour 
IOP measurements were not influenced by IOP reducing 
medication.
randomization and surgeries
Prior to distribution of  OVD packages, patients were 
assigned to a number, which was randomized to either the 
DisCoVisc OVD group or the Healon OVD group. The 
two OVDs were provided to each surgical site in identical, 
sealed, plain cartons. The outside of each carton was labeled 
with the study protocol number, the investigator number, 
and the patient number. Each masked carton was opened 
just before the beginning of the intended surgery. Inside 
the cartons, Healon OVD was supplied as one syringe of 
0.85 mL, and DisCoVisc OVD was supplied as two syringes 
of 0.5 mL each. Because of these differences, the surgeons 
became unmasked to the identity of the OVDs during the 
procedure. For each patient, a disclosure envelope to reveal 
OVD assignment was available, but was to be opened only 
if a serious adverse event occurred.
During surgery, multiple procedures were not allowed 
(eg, no concurrent trabeculoplasty or corneal transplant), 
but minor relaxing keratotomy for the correction of astig-
matism was permitted. Standard clear corneal incisions, 
capsulorhexis, and phacoemulsification were performed. 
All phacoemulsification machines were longitudinal (no 
torsional or transversal modes). Ultrasound time and surgery 
duration were not recorded. Only approved IOLs were used; 
investigational IOLs were not permitted.
At the completion of every surgery, each of the nine 
investigators completed a survey. Three questions addressed 
anterior chamber and dome maintenance (during capsulo-
tomy, during phacoemulsification, and during IOL insertion), 
with four response options, as follows: flat, shallow, working 
space maintained, or full chamber maintained. Three further 
questions addressed the surgeon’s perceived rheological 
properties of the viscoelastic during capsulorhexis, during 
phacoemulsification, and during removal of the OVD. The 
five response options were as follows: dispersive, moder-
ately dispersive, dispersive and cohesive, moderately cohe-
sive, and cohesive. The questionnaire was not a validated 
instrument.
Postoperative assessment and analysis
During the follow-up period of the study, no corneal laser 
surgeries were permitted for the operative eyes. Follow-up 
appointments were scheduled for 6 ± 2 hours, 24 ± 4 hours, 
7 ± 2 days, 30 ± 7 days, and 90 ± 14 days. At each of these 
appointments, IOP and adverse events were recorded. 
All appointments at 1 day postoperative and later included 
assessments of corrected distance Snellen visual acuity and 
of ocular signs by slit-lamp examination. Ocular signs 
included cells, flare, and corneal edema. Ocular signs were 
considered clinically significant if .50 cells were observed 
or if flare or edema were rated “severe” (on a scale of none, 
mild, moderate, or severe). At the final visit, endothelial cell 
density images were recorded. Examiners were masked to 
treatment type at all postoperative visits.
Statistical analyses were performed using SAS for 
Windows (v 9.0; SAS Institute Inc, Cary, NC) and Micro-
soft Excel (v 2002; Microsoft Corp, Redmond, WA), with 
statistical significance set at P , 0.05. Primary efficacy 
variables were incidence of postoperative IOP $ 30 mmHg 
and changes from baseline in corneal endothelial cell density. 
Primary safety variables included ocular signs and adverse 
events. The evaluations of the OVDs by the surgeons were 
secondary efficacy variables.
Results
A total of 249 eyes were enrolled in the study, with 128 eyes 
in the DisCoVisc OVD group and 121 eyes in the Healon 
OVD group. The two groups were statistically similar in 
age, gender, race, iris color, preoperative IOP, and baseline 
endothelial cell density (all P . 0.1), as shown in Table 1. For 
all patients, disclosure envelopes were returned to the study Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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sponsor with seals intact, indicating that no unmasking of 
analysts to treatment type had occurred. All 249 patients had 
at least one postoperative follow-up visit and all patients were 
included in the analyses of safety and surgical performance. 
Missed visits were as follows: one patient in each group at 
6 hours postoperative, two patients in the DisCoVisc OVD 
group at 7 days postoperative, and one patient in each group 
at 30 days postoperative. Nine patients (four in the Healon 
OVD group and five in the DisCoVisc OVD group) were 
excluded from the IOP and endothelial cell density analyses 
because of protocol violations, including deviations from 
exclusion/inclusion criteria or use of an off-protocol medica-
tion with the surgery.
iOP with time
Of the 240 patients without protocol violations, an additional 
12 patients (eight in the DisCoVisc OVD group and four in the 
Healon OVD group) were excluded from IOP analysis. Patients 
were excluded from the IOP analysis if the IOP measurement 
at 6 ± 2 hours postoperative was missing or was more than 
30 minutes early (ie, if the measurement intended for 4–8 hours 
postoperative was recorded at 3 hours and 29 minutes postop-
erative or earlier). The resultant evaluable population was 115 
eyes in the DisCoVisc OVD group and 113 eyes in the Healon 
OVD group. Mean IOPs with time are shown in Figure 1. Mean 
IOPs were statistically similar between OVD groups at all time 
points. All mean IOPs were at least 8 mmHg lower than the 
prespecified safety limit of 30 mmHg.
At 6 hours after surgery, both OVD groups had 15 
patients with IOP $ 30 mmHg, yielding a similar percent-
age of patients with IOP $ 30 mmHg (13.0% of DisCo-
Visc OVD patients, 13.3% of Healon OVD patients). At 
24 hours after surgery, both OVD groups had seven patients 
with IOP $ 30 mmHg (similar between groups, at 6.1% 
of   DisCoVisc OVD patients and 6.2% of Healon OVD 
patients). By postoperative day 7, only one Healon OVD 
patient (0.9% of cases) and no DisCoVisc OVD patients 
had IOP $ 30 mmHg. No IOPs $ 30 mmHg were observed 
in any patient following postoperative day 13. Overall, 
similar percentages of patients in the DisCoVisc OVD group 
(17 of 115, 14.8% of patients) and the Healon OVD group 
(18 of 113, 15.9% of patients) had an IOP $ 30 mmHg at 
any time during the study. The total numbers of patients 
with IOP $ 30 mmHg that were treated with IOP-reducing 
therapy at any visit were 12 patients in the DisCoVisc OVD 
group and 11 patients in the Healon OVD group.
endothelial cell density
Of the 240 patients without protocol violations, one patient 
in the Healon OVD group was excluded from the endothe-
lial cell density analysis because the image of her eye was 
captured at the peripheral cornea instead of the central cor-
neal. For the remaining evaluable 116 Healon OVD patients 
and 123   DisCoVisc OVD patients, the percentage loss of 
endothelial cell density from baseline to postoperative day 
90 was lower for eyes in the DisCoVisc OVD group (average 
6.4% loss, with a 95% confidence interval [CI] range: ±2.3% 
loss) than for eyes in the Healon OVD group (average 8.8% 
loss, with a 95% CI range: ±2.3%). The percentage loss of 
endothelial cell density was not statistically different between 
groups (P = 0.15 by analysis of variance). The distribution – 
  minimum, median, maximum, and quartiles – of percentage 
loss of endothelial cell density is shown in Figure 2.
surgical performance of OVDs
Viscosity characteristics of the OVDs, as assessed subjec-
tively by the nine surgeons, are shown for three  surgical 
stages in Figure 3. The Healon OVD was rated as cohesive 
in the majority of cases for each surgical stage: 69% of cases 
during capsulorhexis, 85% of cases during phacoemulsifi-
cation, and 89% of cases during OVD removal. In contrast, 
the DisCoVisc OVD was most frequently rated as “both 
dispersive and cohesive” during each surgical stage: 45% of 
cases during capsulorhexis, 56% of cases during phacoemul-
sification, and 51% of cases during OVD removal. During 
capsulorhexis and phacoemulsification, the characterizations 
Table 1 Preoperative demographics
DisCoVisc  
OVD group,  
n = 128
Healon  
OVD group,   
n = 121
Age, years 70 ± 10 69 ± 9
gender
  Men (%) 37% 37%
  Women (%) 63% 63%
race
  Caucasian (%) 96.7% 90%
  Black (%) 1.6% 4%
  Asian (%) 0% 1%
  hispanic (%) 1.6% 3%
  Other (%) 0% 2%
iris color
  Brown (%) 27% 36%
  hazel (%) 24% 23%
  green (%) 7% 1.7%
  Blue (%) 42% 38%
  grey (%) 0% 1.7%
intraocular pressure (mmhg) 17.7 ± 2.0 16.9 ± 2.2
endothelial cell density (cells/mm2) 2600 ± 300 2600 ± 300
Abbreviation: OVD, ophthalmic viscosurgical device.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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“full chamber maintained” during each surgical stage: 81% 
of cases during capsulorhexis, 78% of cases during pha-
coemulsification, and 87% of cases during IOL insertion. 
When using the Healon OVD, surgeons most frequently 
rated workspace as “workspace maintained” during each 
surgical stage: 37% of cases during capsulorhexis, 48% 
of cases during phacoemulsification, and 49% of cases 
during IOL insertion. No cases were rated as having “flat” 
or “shallow” workspaces during any of the three surgical 
stages when using the DisCoVisc OVD, but those ratings 
were given to Healon OVD cases in 32% of anterior cap-
sulotomies, in 23% of phacoemulsification stages, and in 
3% of IOL insertions. During all three surgical stages, the 
characterizations of space maintenance by the OVDs were 
statistically different between OVD groups (P , 0.0001 by 
Cochran–Mantel–Haenszel test).
safety and adverse events
No patient in either OVD group exhibited ocular flare that 
merited a clinically significant score at any of the postopera-
tive examinations. For the aqueous cells parameter, three 
eyes exhibited clinically significant scores: two eyes in the 
Healon OVD group (one eye at 1 day postoperative and one 
eye at 7 days postoperative) and one eye in the DisCoVisc 
OVD group at an unscheduled visit (41 days postoperative). 
The latter case was not related to the OVD, but was attrib-
uted to residual lens fragments after surgery in an eye with 
a very small pupil, and was resolved after treatment with 
prednisolone acetate and atropine. Severe corneal edema 
was observed in one eye in the DisCoVisc OVD group and 
in one eye in the Healon OVD group; both cases occurred 
1 day postoperative. The most frequently reported clinical 
observations of events related to the safety and tolerability of 
DisCoVisc OVD group,
n = 113 to 115 at all points
Healon OVD group,
n = 112 to 113 at all points
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of DisCoVisc OVD were skewed toward the dispersive side 
($32% of cases rated “dispersive” or “moderately disper-
sive”).   During OVD removal, the characterizations of Dis-
CoVisc OVD were skewed toward the cohesive side (37% of 
cases rated “cohesive” or “moderately cohesive”.) During 
all three surgical stages, the characterizations of the OVD 
properties were statistically different between OVD groups 
(P , 0.0001 by Cochran–Mantel–Haenszel test).
Space-maintaining characteristics of the OVDs, as 
assessed subjectively by the nine surgeons, are shown for 
three surgical stages in Figure 4. When using the DisCoVisc 
OVD, surgeons most frequently rated the workspace as Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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the OVDs occurred in both study groups and included ocular 
discomfort, conjunctival hyperemia, conjunctival injection, 
or conjunctival erythema.
Discussion
In this large, controlled study that did not use prophylactic 
IOP-lowering medications, the viscous dispersive DisCoVisc 
OVD group had an IOP profile that was similar to IOP profile 
of the cohesive Healon OVD comparator group. At 6 hours 
after surgery, the prevalence of eyes having IOP $ 30 mmHg 
was 13% in both OVD groups. This prevalence is in accor-
dance with values that were previously reported for eyes 
that received the cohesive Healon OVD during cataract 
surgery,13 as shown in Table 2. The prevalence is lower than 
values reported for eyes that received the dispersive Viscoat 
OVD (Alcon) during cataract surgery (23%–29% of eyes in 
Viscoat OVD groups, Table 2).14–16 Judging by IOP profile, 
DisCoVisc OVD behaved more like a cohesive OVD than 
like the dispersive OVD Viscoat, even though the chemical 
compositions of the DisCoVisc and Viscoat OVDs are very 
similar.
The rheological properties of any OVD arise from 
the monomer type and polymer formulation of its 
  constituents. In some cases, these constituents provide 
not only physical protection, but also chemical protection. 
DisCoVisc viscoelastic contains two biologically relevant 
glycosaminoglycans: 1.6% hyaluronic acid (also found in 
connective tissues) and 4% chondroitin sulfate (also found 
in cartilage).1,17 Both chondroitin sulfate and hyaluronic 
acid are antioxidants.18 During an in vitro simulation of 
phacoemulsification, an OVD containing 3% chondroitin 
sulfate and 4% hyaluronic acid (Viscoat OVD) suppressed 
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free radicals significantly more than an OVD containing 
2.3% hyaluronic acid alone (Healon5 OVD, Advanced 
Medical Optics, Inc).15 The   relative chemical and rheo-
logical protective effects of various OVDs are not yet fully 
understood.
With regard to the protection of endothelial cells in the 
current study, the percentage cell loss with the DisCoVisc 
OVD (average 6.4% loss) was lower than with the Healon 
OVD comparator (average 8.8% loss), though the differ-
ence was not statistically significant. It is not clear whether 
the endothelial protection provided by the OVDs was due 
to rheological properties, to chemical/antioxidant content, 
or to a combination of both. Protection could be related to 
endothelium-coating properties of the OVDs. Two stud-
ies using animal eyes found that a thin uniform layer of 
  DisCoVisc OVD remained as a lining on the inner cornea 
after phacoemulsification and removal of OVD; the inves-
tigators suggested that this coating was indicative of the 
protective effects of the DisCoVisc OVD.19,20 The residual 
layer of DisCoVisc OVD (325 µm ± 164) was significantly 
thicker than the residual layer of Healon OVD (4 ± 11 µm).20 
The coating behavior of an OVD may partially explain its 
protection of the endothelium.
The values of percentage loss of endothelial cells in the 
current study (6.4% loss in the DisCoVisc OVD group and 
8.8% loss in the Healon OVD group) are near the low end 
of ranges found in similar studies, which reported aver-
ages of 4%–19% loss.21–23 Results with DisCoVisc OVD in 
the current study are in accord with a literature report of 
4% loss for 50 eyes that received DisCoVisc OVD during 
cataract surgery.23 The DisCoVisc OVD results presented 
here are also similar to percentage loss reported for eyes 
that received the viscoadaptive Healon5 OVD (6% loss)22 
and eyes that received DuoVisc OVD with the soft-shell 
technique (5% loss).23
In this study, surgeons subjectively rated DisCoVisc 
OVD as statistically superior to Healon OVD in   maintaining 
  anterior chamber space during anterior capsulotomy, and 
found that the DisCoVisc OVD demonstrated both cohesive 
and dispersive properties during capsulorhexis. It may be 
important that 32% of surgeons rated the anterior chamber 
as flat or shallow during capsulorhexis when using Healon 
OVD. Incision creation and capsulorhexis are important 
stage-setting steps in determining the ease and success 
of a cataract surgery. It would be important to distinguish 
whether surgeons gave the OVDs grades for maintenance 
of space that depended on their capsulorhexis techniques, 
either via cystotome only or via cystotome initiation and 
forceps completion. These surgical techniques were not 
recorded during this study. Surgeons using cystotomes only 
for capsulotomy may find that their opinion of chamber space 
maintenance may be affected by the friction on the needle 
under the influence of the OVD.
In addition to capsulotomy results, surgeons in this study 
also subjectively rated DisCoVisc OVD as statistically supe-
rior to Healon OVD in maintaining anterior chamber space 
during phacoemulsification and IOL insertion. Surgeons also 
found that the DisCoVisc OVD demonstrated both cohesive 
and dispersive properties during phacoemulsification and 
removal of OVD. This subjective judgement of the rheo-
logical properties of the DisCoVisc OVD is in accordance 
with findings of a smaller clinical trial (n = 35)24 and with 
benchtop experiments that found the DisCoVisc OVD had 
both cohesive and dispersive qualities, meriting the new 
classification, “viscous dispersive”.2 During OVD removal 
in this study, the characterizations of DisCoVisc OVD were 
Table 2 Percentage of eyes with intraocular pressure $ 30 mmhg at 6 hours after cataract surgery, as reported in various studies of 
ophthalmic viscosurgical devices
Reference Ophthalmic viscosurgical devices (OVDs) Eyes, n Eyes $ 30 
mmHg, % OVD name Composition Character
This study DisCoVisc 1.6% sh, 4% Cs Viscous dispersive 128 13%
Healon 1% sh Cohesive 121 13%
rainer et al16 Viscoat 4% Cs, 3% sh Dispersive 35 29%
Healon5 2.3% sh Viscoadaptive 35 6%
rainer et al14 Viscoat 4% Cs, 3% sh Dispersive 40 23%
Ocucoat 2% hPMC Dispersive 40 5%
rainer et al15 Viscoat 4% Cs, 3% sh Dispersive 38 26%
rainer et al13 Healon 1% sh Cohesive 40 13%
Ocucoat 2% hPMC Dispersive 40 10%
Abbreviations: Cs, chondroitin sulfate; hPMC, hydroxypropyl methylcellulose; sh, sodium hyaluronate.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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skewed toward the cohesive side. This result is in accordance 
with the results of an animal study in which the speed of 
DisCoVisc OVD removal was second only to the removal 
of the cohesive Provisc OVD (Alcon Laboratories, Inc) in 
an array of four different OVDs.25 Similarly, another animal 
study found that fluorescein-stained DisCoVisc OVD stayed 
in the eye during phacoemulsification and then was removed 
in a single mass at the end of the procedure.26
One uncontrolled variable in this study was surgical 
  technique. Some researchers have reported that endothelial 
cell loss was less with the phaco-chop technique than with the 
divide-and-conquer technique,27,28 though other researchers 
have found that the two methods produced similar endothelial 
outcomes.29 It would be interesting to know whether patients 
treated by one particular surgeon in this study received dif-
ferent benefits due to surgical technique, but surgical tech-
niques were not recorded in this study. Moreover, identifying 
beneficial surgical strategies would be helpful in establishing 
practices to use the OVDs to greatest advantage.
Conclusion
This study found that the DisCoVisc OVD had rheological 
characteristics that made it suitable for the entire surgical 
procedure, and that DisCoVisc OVD was safe, well-tolerated, 
and protective in eyes undergoing cataract extraction and 
IOL implantation.
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